Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy Fernand Labrie, MD, PhD, Leonard Derogatis,

Slides:

Advertisements

Similar presentations

Young Woman With Abdominal Pain David Jones, MD Annals of Emergency Medicine Volume 64, Issue 4, (October 2014) DOI: /j.annemergmed

Advertisements

Image Postprocessing in Digital Radiology—A Primer for Technologists Euclid Seeram, RTR, BSc, MSc, FCAMRT, David Seeram Journal of Medical Imaging and.

Risk-Reducing Salpingectomy in Canada: A Survey of Obstetrician-Gynaecologists Clare J. Reade, MD, MSc, Sarah Finlayson, MD, Jessica McAlpine, MD, Alicia.

An Unusual Electrocardiogram in a Heart Transplant Recipient Hamish I. MacLachlan, BSc, MBBS, Jonathan R. Dalzell, MD, MRCP The American Journal of Medicine.

Impact of End-Stage Kidney Disease on Academic Achievement and Employment in Young Adults: A Mixed Methods Study Peter D. Murray, Fabienne Dobbels, Ph.D.,

Health Benefits of Nordic Walking

How Well Is Acute Pain in Children Managed

Satisfaction with and Intention to Continue Depo-Provera Versus the Mirena IUD among Post-Partum Adolescents through 12 Months of Follow-Up David L.

A Nationwide Survey of Quality of End-of-Life Cancer Care in Designated Cancer Centers, Inpatient Palliative Care Units, and Home Hospices in Japan: The.

Volume 54, Issue 4, Pages (October 1998)

Mindfulness Meditation Modulates Pain Through Endogenous Opioids

Sexuality The American Journal of Medicine

Comparative Effectiveness Research and Medical Informatics

Evaluation of a Web-Based Palliative Care Pain Management Module for Housestaff Sydney Morss Dy, MD, MSc, Mark Hughes, MD, MA, Carlos Weiss, MD, MHS,

James H. Liu, MD The American Journal of Medicine

Louise C. Brown, PhD, B'Eng, MSc, Simon G. Thompson, DSc, MA, Roger M

Mindfulness Meditation Modulates Pain Through Endogenous Opioids

Risk-taking Behavior in Skiing Among Helmet Wearers and Nonwearers

Age at menarche: a predictor of diminished ovarian function?

Procedural Sedation: Is Two Better Than One?

Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial Dana A. Muin, M.D., M.Sc.,

Reduction of C-reactive protein levels through use of a multivitamin

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Colin Powell, BSc (tech) FHEA Wilderness & Environmental Medicine

Accuracy of a home-based device for giving an early estimate of pregnancy duration compared with reference methods Sarah R. Johnson, Ph.D., Sonya Godbert,

Epidemiology of Myelodysplastic Syndromes

Ramifications of adolescent menstrual cycles ≥42 days in young adults

A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women Ljiljana.

Ivana M. M. van der Geest, BSc, Anne-Sophie E

Managing female sexual dysfunction

Metabolic Syndrome and Sexual Function in Postmenopausal Women

Genitourinary symptoms in the menopausal transition

Comparison of Seven-Day and Repeated 24-Hour Recall of Symptoms in the First 100 Days After Hematopoietic Cell Transplantation William A. Wood, MD, MPH,

Gender Differences Among Long-Distance Backpackers: A Prospective Study of Women Appalachian Trail Backpackers David R. Boulware, MD Wilderness & Environmental.

Repeated Hemoglobin A1C Ordering in the VA Health System

Ankle-Brachial Index on Kilimanjaro: Lessons from High Altitude

Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis

Managing Medicines for Patients Dying at Home: A Review of Family Caregivers' Experiences Eleanor Wilson, PhD, MSc, BA, Glenys Caswell, PhD, MRes, BA,

Christian Stief European Urology Supplements

Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial David Hui, MD, MSc, Kelly.

Sean Ackerman, M. D. , Julia Wenegrat, M. A. , David Rettew, M. D

Douglas McGraw, Stephen J. Gluckman, MD

Recreational Injuries in Washington State National Parks

Sophia C. Kamran, William F. Pendergraft, MD, David C

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Society for Investigative Dermatology 2010 Meeting Minutes

Marie-Andrée Harvey, MD, MSc

Ari Sanders, MD, R. Douglas Wilson, MD, MSc, FRCSC

Reviewer Acknowledgment

Delayed orgasm and anorgasmia

Using bilateral internal thoracic arteries—just do it

Volume 54, Issue 4, Pages (October 1998)

A longitudinal study of the effects of free testosterone and other psychosocial variables on sexual function during the natural traverse of menopause

In vitro fertilization and breast cancer: is there cause for concern?

Estrogen therapy increases plasma concentrations of nitric oxide metabolites in postmenopausal women but increases flow-mediated vasodilation only in.

Genome-wide linkage analysis to age at natural menopause in a community-based sample: the Framingham Heart Study Joanne M. Murabito, M.D. Sc.M., Qiong.

Ovarian expression of markers associated with proliferation or apoptosis in women with diminished ovarian reserve Víctor Vital-Reyes, M.D., M.Sc., Cristina.

A critique of the Women’s Health Initiative hormone therapy study

Adam M. Anderson, MD, John M. Leisey, MD

Ivan Mazzon, M. D. , Alessandro Favilli, M. D. , Mario Grasso, M. D

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women Sara J. Mucowski, M.D.,

A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage Alka Prakash,

Bhagwan Satiani, MD, MBA, Thomas E. Williams, MD, PhD, Michael R

Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women:

Hormones, mood, sexuality, and the menopausal transition

Mobile Medicine: Digital Dynamo or Virtual Vaporware

Does the menopausal transition affect health-related quality of life?

Marita Pall, M. D. , Ph. D. , Margaret Nguyen, B. S

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Presentation transcript:

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy Fernand Labrie, MD, PhD, Leonard Derogatis, PhD, David F. Archer, MD, William Koltun, MD, Andrée Vachon, MD, Douglas Young, MD, Louise Frenette, MD, David Portman, MD, Marlene Montesino, MD, Isabelle Côté, BSc, Julie Parent, PhD, Lyne Lavoie, MSc, Adam Beauregard, BSc, MBA, Céline Martel, PhD, Mario Vaillancourt, BSc, MBA, John Balser, PhD, Érick Moyneur, BSc, MA The Journal of Sexual Medicine Volume 12, Issue 12, Pages 2401-2412 (December 2015) DOI: 10.1111/jsm.13045 Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 1 Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the desire domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 2 Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the arousal domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 3 Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the lubrication domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 4 Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the orgasm domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 5 Effect of daily intravaginal application of 0.0% (n=149) and 0.50% (n=300) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the satisfaction domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals. *In this domain, few women were excluded since they have not answered one and/or two questions related to sexual activity with a partner. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 6 Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the pain domain of Female Sexual Function Index (FSFI) in post-menopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

Figure 7 Effect of daily intravaginal application of 0.0% (n=149) and 0.50% (n=300) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the total score of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals. *Few women were excluded from the total score as they have not answered some questions in the satisfaction domain. The Journal of Sexual Medicine 2015 12, 2401-2412DOI: (10.1111/jsm.13045) Copyright © 2015 International Society for Sexual Medicine Terms and Conditions